Literature DB >> 20819010

Cognitive-behavioral therapy: what benefits can it offer people with multiple sclerosis?

Laura Dennison1, Rona Moss-Morris.   

Abstract

Cognitive-behavioral therapy (CBT) originated as a treatment for emotional disorders. However, it is increasingly used to help people with chronic illnesses manage symptoms and improve psychosocial outcomes, such as depression and quality of life. In this article, we focus on uses of CBT in patients with multiple sclerosis, an incurable neurological disease that causes potentially debilitating symptoms and poses numerous challenges to psychological well-being. We examine the rationale for using CBT to deal with distress, symptoms, impairment and disease exacerbation and progression, and discuss examples of existing research on the efficacy and acceptability of these interventions. Finally, we consider areas where CBT could potentially benefit people with multiple sclerosis in the future. Ongoing challenges in this field are discussed.

Entities:  

Mesh:

Year:  2010        PMID: 20819010     DOI: 10.1586/ern.10.111

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  12 in total

1.  Polypharmacy in Multiple Sclerosis: Current Knowledge and Future Directions.

Authors:  Joanie Thelen; Valeriy Zvonarev; Sarah Lam; Crystal Burkhardt; Sharon Lynch; Jared Bruce
Journal:  Mo Med       Date:  2021 May-Jun

2.  Depression and Age at First Neurology Appointment Associated with Receipt of Behavioral Medicine Services Within 1 Year in a Multiple Sclerosis Population.

Authors:  Benjamin Greenberg; Youran Fan; Lucille Carriere; Amy Sullivan
Journal:  Int J MS Care       Date:  2017 Jul-Aug

Review 3.  Current controversies on the role of behavior therapy in Tourette syndrome.

Authors:  Lawrence Scahill; Douglas W Woods; Michael B Himle; Alan L Peterson; Sabine Wilhelm; John C Piacentini; Kevin McNaught; John T Walkup; Jonathan W Mink
Journal:  Mov Disord       Date:  2013-05-16       Impact factor: 10.338

4.  Impact of depression, fatigue, and global measure of cortical volume on cognitive impairment in multiple sclerosis.

Authors:  Domenica Nunnari; Maria Cristina De Cola; Giangaetano D'Aleo; Carmela Rifici; Margherita Russo; Edoardo Sessa; Placido Bramanti; Silvia Marino
Journal:  Biomed Res Int       Date:  2015-03-11       Impact factor: 3.411

Review 5.  Cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: a systematic review and meta-analysis.

Authors:  Daniel Hind; Jack Cotter; Anna Thake; Mike Bradburn; Cindy Cooper; Claire Isaac; Allan House
Journal:  BMC Psychiatry       Date:  2014-01-09       Impact factor: 3.630

6.  Cognitive-behavioural therapy (CBT) for renal fatigue (BReF): a feasibility randomised-controlled trial of CBT for the management of fatigue in haemodialysis (HD) patients.

Authors:  Federica Picariello; Rona Moss-Morris; Iain C Macdougall; Sam Norton; Maria Da Silva-Gane; Ken Farrington; Hope Clayton; Joseph Chilcot
Journal:  BMJ Open       Date:  2018-03-08       Impact factor: 2.692

7.  Polypharmacy in patients with multiple sclerosis: a gender-specific analysis.

Authors:  Niklas Frahm; Michael Hecker; Uwe Klaus Zettl
Journal:  Biol Sex Differ       Date:  2019-05-27       Impact factor: 5.027

8.  Multi-drug use among patients with multiple sclerosis: A cross-sectional study of associations to clinicodemographic factors.

Authors:  Niklas Frahm; Michael Hecker; Uwe Klaus Zettl
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

9.  Psychological well-being in people with multiple sclerosis in an Iranian population.

Authors:  Sedigheh Rezaei Dehnavi; Fatemeh Heidarian; Fereshteh Ashtari; Vahid Shaygannejad
Journal:  J Res Med Sci       Date:  2015-06       Impact factor: 1.852

10.  Cost-effectiveness of nurse-delivered cognitive behavioural therapy (CBT) compared to supportive listening (SL) for adjustment to multiple sclerosis.

Authors:  I Mosweu; R Moss-Morris; L Dennison; T Chalder; P McCrone
Journal:  Health Econ Rev       Date:  2017-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.